Provided by Tiger Trade Technology Pte. Ltd.

Annovis Bio, Inc.

2.01
-0.0200-0.99%
Pre-market: 1.99-0.0169-0.84%04:29 EDT
Volume:360.42K
Turnover:725.53K
Market Cap:56.99M
PE:-1.43
High:2.05
Open:2.03
Low:1.96
Close:2.03
52wk High:5.50
52wk Low:1.11
Shares:28.36M
Float Shares:24.26M
Volume Ratio:0.76
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4040
EPS(LYR):-1.4040
ROE:-220.61%
ROA:-106.03%
PB:3.38
PE(LYR):-1.43

Loading ...

Annovis Bio Inc - CEO Maria Maccecchini to Serve as Acting CFO Until Replacement Is Identified - SEC Filing

THOMSON REUTERS
·
Mar 26

Annovis Bio Inc - Mark Guerin Steps Down as CFO Effective March 23, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 26

Annovis Bio CFO Mark Guerin departs; CEO Maria Maccecchini becomes acting CFO effective March 23, 2026

Reuters
·
Mar 26

Annovis Bio enters partnership with NeuroRPM

TIPRANKS
·
Mar 19

Annovis Bio partners with NeuroRPM for AI wearable monitoring in Parkinson’s trial

Reuters
·
Mar 19

Annovis Bio partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study

Reuters
·
Mar 19

Neurorpm to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

THOMSON REUTERS
·
Mar 19

Analysts Offer Insights on Healthcare Companies: Warby Parker (WRBY) and Annovis Bio (ANVS)

TIPRANKS
·
Mar 19

BRIEF-Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial Results

Reuters
·
Mar 16

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

TIPRANKS
·
Mar 16

Annovis Bio Q4 EPS $(0.39) Misses $(0.34) Estimate

Benzinga
·
Mar 16

Annovis Bio Inc: Estimates That Its Current Cash and Cash Equivalents Will Enable It to Fund Its Operations Into Q3 of 2026

THOMSON REUTERS
·
Mar 16

Press Release: Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Dow Jones
·
Mar 16

Annovis Bio FY 2025 net loss widens 17% to USD 28.86 million, interest income rises 111% to USD 0.7 million

Reuters
·
Mar 14

Annovis Bio to Present Twice at AD/PD 2026 International Conference

Reuters
·
Mar 03

Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating

TIPRANKS
·
Feb 21

Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod

TIPRANKS
·
Feb 12

Annovis Bio Inc - Dsmb Finds No Safety Concerns, Trial to Continue as Planned

THOMSON REUTERS
·
Feb 12

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

GlobeNewswire
·
Feb 12

Annovis Bio Hosts Regulation FD Investor Information Webinar

TIPRANKS
·
Jan 29